Hongtu Yuan

Higher proximity of PD-L1+ tumor cells to PD-1+ tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

Yimin Zhao, Yushan Yan, Liying Yang, Miaoqing Zhao et autres

Background: Although neoadjuvant chemoimmunotherapy (NCIT) improves outcomes in resectable non-small cell lung cancer (NSCLC), traditional biomarkers like programmed death-ligand 1 (PD-L1) expression are insufficient for accurate patient selection. This study aimed to investigate the spatial interaction between specific T-cell subsets and PD-L1+ …

cn (code pays fourni par la source)

Data from Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial

Heng Fu, Zengjun Liu, Mengyao Liu, Jing Xu et autres

Abstract Advanced sarcomas have limited treatment options after standard therapy, and therefore we investigated the efficacy and safety of sintilimab plus anlotinib in this setting. Patients age 18 to 75 years with advanced sarcomas and prior systemic therapy were enrolled. Patients with …

Supplementary Table 2 from Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial

Heng Fu, Zengjun Liu, Mengyao Liu, Jing Xu et autres

Representativeness of Study Participants

Supplementary Table 1 from Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial

Heng Fu, Zengjun Liu, Mengyao Liu, Jing Xu et autres

raw data

First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial

Jingyu Zhao, Zengjun Liu, Heng Fu, Mengyao Liu et autres

PURPOSE: This study evaluated the efficacy and safety of first-line anlotinib combined with anthracyclines and ifosfamide, followed by anlotinib maintenance therapy, in patients with advanced soft-tissue sarcoma. PATIENTS AND METHODS: Patients received four to six cycles of combination therapy administered every 21 …

cn (code pays fourni par la source)

Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial

Heng Fu, Zengjun Liu, Mengyao Liu, Jing Xu et autres

Advanced sarcomas have limited treatment options after standard therapy, and therefore we investigated the efficacy and safety of sintilimab plus anlotinib in this setting. Patients age 18 to 75 years with advanced sarcomas and prior systemic therapy were enrolled. Patients with untreated, …

cn (code pays fourni par la source)

Closer proximity of pre-treatment CD4+ T cells to CD8+ T cells favor response to neoadjuvant immunotherapy in patients with PD-L1 low-expressing non-small cell lung cancer

Liying Yang, Jiaxiao Geng, Hao Yang, Miaoqing Zhao et autres

Background: Neoadjuvant chemo-immunotherapy improves non-small cell lung cancer (NSCLC) outcomes, but remission rates vary, emphasizing the need for biomarkers. This study aimed to investigate the impact of the baseline intratumoral CD4+ T-cell-adjacent microenvironment on the efficacy of neoadjuvant immunotherapy in NSCLC and …

cn (code pays fourni par la source)

Stage-dependent spatial distribution and prognostic value of CD8+ tissue-resident memory T cells in NSCLC

Liying Yang, Hao Yang, Miaoqing Zhao, Hongtu Yuan et autres

CD8 + tissue-resident memory T cells (CD8 + T RM ), expressing PD-1 and/or TIM-3, are linked to immunological surveillance in non-small cell lung cancer (NSCLC). However, their prognostic value across activation states and spatial distributions in NSCLC stages is unclear. We …

cn (code pays fourni par la source)

Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study

Yifan Gao, Haoqian Li, Lei Qiu, Hongtu Yuan et autres

PURPOSE: Programmed death-1 antibody plus chemotherapy has gained approval for the treatment for (human epidermal growth factor receptor 2 negative locally advanced or metastatic gastric or gastroesophageal junction cancer. This study aims to analyze the efficacy and safety of anti-programmed death-1 antibody …

cn (code pays fourni par la source)

Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies

Yajing Chi, Hongtu Yuan, Qing Fan, Zhendan Wang et autres

This study delineated the elucidate molecular changes and their post-translational modifications (PTMs) in heterogenetic colorectal cancer (CRC) for a deeper understanding of the CRC pathophysiology and identifying potential therapeutic targets. In this retrospective study, the profiles of 13 hot spot gene mutations …

cn (code pays fourni par la source)

A Case of Uterine Endometrial Stromal Sarcoma with CIC Translocation and Literature Review

Fenghou Wang, Hongtu Yuan, Jing Yang, Li Li et autres

cn (code pays fourni par la source)

Aspergillus ball crawling out of pulmonary bullae

Yuhui Liu, Hongtu Yuan, Yong Huang

Chest CT images of the patient in 2016, 2017, 2018, and 2019. The lesion was significantly larger compared with its size in 2016.

cn (code pays fourni par la source)